---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-23-000047"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T18:28:00.292048+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zentalis FY2022 cash $437M, R&D $172.7M; azenosertib RP2D on track for 1H 2023

## Summary
- Cash, cash equivalents and marketable securities of $437.4M as of Dec 31, 2022; projected cash runway into Q2 2025.
- R&D expenses $172.7M for FY2022 (vs $175.6M in 2021); G&A expenses $54.5M (vs $40.9M).
- On track to declare azenosertib monotherapy RP2D in 1H 2023; Cyclin E1 enrichment strategy in ovarian cancer.
- Appointed Iris Roth, PhD as Chief Operating Officer in February 2023.
- Initiated enrollment in Phase 1/2 azenosertib + BEACON regimen (Pfizer) in BRAF V600E mCRC.

## SEC filing metadata
- accession: 0001725160-23-000047
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000047/0001725160-23-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000047/zntl-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-23-000047
- JSON: https://secwatch.observer/filing/0001725160-23-000047.json
- Plain text: https://secwatch.observer/filing/0001725160-23-000047.txt

## Key facts
- Earnings Releases
  Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000047/0001725160-23-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.